Clinical Trial: A Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined with Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients with Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma (China)

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined with Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients with Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131924

Registration Time: 2026/09/07

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Xiamen University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342208

Published by HT Digital Content Services ...